CancerDrs

Breast Cancer clinical trials in Nevada

10 actively recruiting breast cancer trials at 5 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Nevada:
  • Carson Tahoe Regional Medical Center — Carson City, Nevada
  • Cancer and Blood Specialists-Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
  • OptumCare Cancer Care at Seven Hills — Henderson, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Nevada:
  • Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
  • Cancer Care & Hematology Specialists — Reno, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…

Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Sites in Nevada:
  • Renown Regional Medical Center — Reno, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Nevada:
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
  • Summerlin Hospital Medical Center — Las Vegas, Nevada
  • OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
  • Renown Regional Medical Center — Reno, Nevada
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Nevada:
  • Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nevada:
  • Carson Tahoe Regional Medical Center — Carson City, Nevada
  • Cancer and Blood Specialists-Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
  • Las Vegas Cancer Center-Henderson — Henderson, Nevada
View on ClinicalTrials.gov →
NA Recruiting Network

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Nevada:
  • Carson Tahoe Regional Medical Center — Carson City, Nevada
  • Cancer and Blood Specialists-Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
  • Las Vegas Cancer Center-Henderson — Henderson, Nevada
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nevada:
  • OptumCare Cancer Care at Seven Hills — Henderson, Nevada
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
View on ClinicalTrials.gov →
Recruiting Industry

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find the…

Sponsor: Tempus AI
NCT ID: NCT07211178
Sites in Nevada:
  • Cancer Care Specialist of Reno — Reno, Nevada
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15